Mode
Text Size
Log in / Sign up
N/A Completed N=6,896

Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use

Prostatic Hyperplasia
Source: ClinicalTrials.gov NCT01332435 ↗
Enrolled (actual)
6,896
Serious AEs
—
Results posted
Jul 2011
Primary outcomePrimary: Number of Participants With Clinical Progression — 176; 202; 266; 232 participants — p=<0.001

Summary

This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy. Both the Integrated Health Care Information Solutions and PharMetrics databases will be utilized for this study (2000-2007).

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Clinical Progression
176; 202; 266; 232 <0.001 sig
PRIMARY
Number of Participants With Acute Urinary Retention
127; 140; 182; 166 <0.001 sig
PRIMARY
Number of Participants Who Needed Prostate-Related Surgery
75; 101; 130; 104 <0.001 sig
SECONDARY
Total BPH-related Costs
1417; 1606; 1735; 1686 <0.001 sig
SECONDARY
BPH-related Medical Costs
349; 618; 344; 449 <0.001 sig
SECONDARY
BPH-related Pharmacy Costs
1068; 1417; 1392; 1237 —

Eligibility Criteria

Inclusion Criteria

  • Male patients aged 50 years or older
  • a medical claim of EP
  • a prescription claim for a 5ARI and AB (provided both are within 180 days of index date)
  • continuously eligible for 6 months prior to and at least 12 months after index prescription date.

Exclusion Criteria

  • diagnosis of prostate or bladder cancer
  • any prostate-related surgical procedure within 5 months of index date
  • prescription claim for finasteride indicative of male pattern baldness
  • 5ARI therapy initiated prior to initiating AB therapy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01332435). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search